ATE423789T1 - Rekombinante mhc-moleküle welche nützlich sind für die manipulation von antigen-spezifischen t- zellen - Google Patents

Rekombinante mhc-moleküle welche nützlich sind für die manipulation von antigen-spezifischen t- zellen

Info

Publication number
ATE423789T1
ATE423789T1 AT98946814T AT98946814T ATE423789T1 AT E423789 T1 ATE423789 T1 AT E423789T1 AT 98946814 T AT98946814 T AT 98946814T AT 98946814 T AT98946814 T AT 98946814T AT E423789 T1 ATE423789 T1 AT E423789T1
Authority
AT
Austria
Prior art keywords
cells
specific
antigen
useful
polypeptides
Prior art date
Application number
AT98946814T
Other languages
English (en)
Inventor
Gregory Burrows
Arthur Vanderbark
Original Assignee
Univ Oregon Health & Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oregon Health & Science filed Critical Univ Oregon Health & Science
Application granted granted Critical
Publication of ATE423789T1 publication Critical patent/ATE423789T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT98946814T 1997-09-16 1998-09-15 Rekombinante mhc-moleküle welche nützlich sind für die manipulation von antigen-spezifischen t- zellen ATE423789T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6455297P 1997-09-16 1997-09-16
US6455597P 1997-10-10 1997-10-10

Publications (1)

Publication Number Publication Date
ATE423789T1 true ATE423789T1 (de) 2009-03-15

Family

ID=26744627

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98946814T ATE423789T1 (de) 1997-09-16 1998-09-15 Rekombinante mhc-moleküle welche nützlich sind für die manipulation von antigen-spezifischen t- zellen

Country Status (12)

Country Link
US (4) US6270772B1 (de)
EP (1) EP1017721B1 (de)
JP (1) JP4485679B2 (de)
AT (1) ATE423789T1 (de)
AU (1) AU741130B2 (de)
CA (1) CA2302779C (de)
CY (1) CY1110274T1 (de)
DE (1) DE69840600D1 (de)
DK (1) DK1017721T3 (de)
ES (1) ES2323098T3 (de)
PT (1) PT1017721E (de)
WO (1) WO1999014236A1 (de)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999014236A1 (en) * 1997-09-16 1999-03-25 Oregon Health Sciences University Recombinant mhc molecules useful for manipulation of antigen-specific t-cells
US20030007978A1 (en) * 1997-09-16 2003-01-09 Burrows Gregory G. Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
WO2000063690A1 (en) * 1999-04-16 2000-10-26 Ortho-Mcneil Pharmaceutical, Inc. Enriched antigen-specific t-cells, and related therapeutic and prophylactic compositions and methods
US7009042B1 (en) * 1999-10-07 2006-03-07 Corixa Corporation Methods of using a Mycobacterium tuberculosis coding sequence to facilitate stable and high yield expression of the heterologous proteins
CA2386854A1 (en) * 1999-10-07 2001-04-12 Corixa Corporation Methods of using a mycobacterium tuberculosis coding sequence to facilitate stable and high yield expression of heterologous proteins
US8609436B2 (en) * 2000-03-17 2013-12-17 Guy's & St Thomas' Hospital NHS Trust (“GST”) Method
US8088586B2 (en) * 2000-03-17 2012-01-03 Oxford Radcliffe Hospital Nhs Trust Method of producing a body fluid sample depleted of anti-MHC antibodies
AU2001261005A1 (en) * 2000-03-22 2001-10-03 Corixa Corporation Immune mediators and related methods
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
CA2440773A1 (en) * 2001-03-14 2002-09-19 Dakocytomation Denmark A/S Novel mhc molecule constructs, and methods of employing these constructs for diagnosis and therapy, and uses of mhc molecules
US8022190B2 (en) 2001-06-19 2011-09-20 Technion Research & Development Foundation Ltd. Immuno-molecules containing viral proteins, compositions thereof and methods of using
US20030144477A1 (en) * 2001-10-04 2003-07-31 Corixa Corporation Immunodominant acetylcholine receptor alpha subunit peptide: MHC complexes
US20030199024A1 (en) * 2002-04-19 2003-10-23 Hansen Ted H. Single chain trimers of class I MHC molecules
US20040072262A1 (en) * 2002-10-11 2004-04-15 Montero-Julian Felix A. Methods and systems for detecting MHC class I binding peptides
US20040248205A1 (en) * 2003-04-16 2004-12-09 Stern Lawrence J. Major histocompatibility complex (MHC)-peptide arrays
US20040225112A1 (en) * 2003-05-06 2004-11-11 Crew Mark D. Genes encoding single chain human leukocyte antigen E (HLA-E) proteins to prevent natural killer cell-mediated cytotoxicity
ATE481476T1 (de) * 2003-05-08 2010-10-15 Life Technologies Corp Erzeugung und isolierung antigenspezifischer t- zellen
US9063145B2 (en) 2003-07-23 2015-06-23 Cellular Technology Limited Multivalent opsonophagocytic assay using bead array and imaging
US7598093B2 (en) * 2003-07-23 2009-10-06 Ctl Analyzers, Llc Nanoparticle and microparticle based detection of cellular products
CA2537759C (en) 2003-09-05 2015-03-24 Oregon Health & Science University Monomeric recombinant mhc molecules useful for manipulation of antigen-specific t cells
WO2005047902A1 (en) * 2003-11-03 2005-05-26 Beckman Coulter, Inc. Solution-based methods for detecting mhc-binding peptides
US7622453B2 (en) 2003-12-23 2009-11-24 Santaris Pharma A/S Oligomeric compounds for the modulation of Bcl-2
JP2007536522A (ja) * 2004-05-07 2007-12-13 ベックマン コールター インコーポレーティッド Ｃｔｌの媒介による抗原提示細胞の溶解を検出するためのｍｈｃ架橋系
EP2226332A1 (de) * 2004-06-17 2010-09-08 Beckman Coulter, Inc. Mycobacterium-tuberculosis-Epitope und Verfahren zu deren Verwendung
WO2006102170A2 (en) * 2005-03-18 2006-09-28 Oregon Health & Science University Recombinant mhc molecules useful for manipulation of antigen-specific t cells
US8133691B2 (en) * 2005-07-06 2012-03-13 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Stable quantitation and detection of immune response levels with non-zero background peptides
US8518697B2 (en) * 2006-04-04 2013-08-27 Washington University Single chain trimers and uses therefor
US7977457B2 (en) 2006-05-19 2011-07-12 Teva Pharmaceutical Industries Ltd. Fusion proteins, uses thereof and processes for producing same
EP2572734B1 (de) 2006-10-31 2016-04-06 East Carolina University Cytokinbasierte Fusionsproteine zur Behandlung von Immunstörungen
EP2126660A2 (de) * 2006-12-01 2009-12-02 The Regents of the University of Michigan Taktverteilungsnetzwerkarchitektur für resonanzgetaktete systeme
WO2008116468A2 (en) 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
EP2167537A2 (de) 2007-07-03 2010-03-31 Dako Denmark A/S Zusammengestellte verfahren für die analyse und sortierung von proben
EP2197908A2 (de) 2007-09-27 2010-06-23 Dako Denmark A/S Mhc-multimere in tuberkulose-diagnostika, -impfstoff und therapeutika
US8406860B2 (en) 2008-01-25 2013-03-26 Novadaq Technologies Inc. Method for evaluating blush in myocardial tissue
US10968269B1 (en) 2008-02-28 2021-04-06 Agilent Technologies, Inc. MHC multimers in borrelia diagnostics and disease
US10722562B2 (en) 2008-07-23 2020-07-28 Immudex Aps Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
US8491913B2 (en) * 2009-03-07 2013-07-23 Oregon Health & Science University Compositions and methods using recombinant MHC molecules for the treatment of stroke
US20110008382A1 (en) * 2009-03-07 2011-01-13 Burrows Gregory G Compositions and methods using recombinant MHC molecules for the treatment of uveitis
EP3348275A3 (de) 2009-03-31 2018-10-24 East Carolina University Cytokine und neuroantigene zur behandlung von immunerkrankungen
US20110110965A1 (en) * 2009-08-26 2011-05-12 Selecta Biosciences, Inc. Compositions that induce t cell help
GB201002730D0 (en) * 2010-02-18 2010-04-07 Uni I Oslo Product
WO2012007950A2 (en) * 2010-07-15 2012-01-19 Technion Research & Development Foundation Ltd. Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and diabetes-associated autoantigenic peptides
EP2593551B1 (de) * 2010-07-15 2016-09-14 Technion Research & Development Foundation Ltd. Isolierte hochaffine einheiten mit t-zell-rezeptorähnlicher spezifität gegenüber nativen komplexen der mhc-klasse ii und autoantigenen gad-peptiden
US20130171179A1 (en) * 2010-09-03 2013-07-04 Oregon Health & Science University Recombinant t-cell receptor ligands with covalently bound peptides
CN105497883A (zh) * 2010-09-29 2016-04-20 乌第有限合伙公司 使用生物相容性的生物可吸收纳米球治疗自身免疫病的方法
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
US8685404B2 (en) 2011-01-31 2014-04-01 Oregon Health & Science University Recombinant T-cell receptor ligand for the treatment of cognitive and neuropsychiatric impairment induced by substance addiction
US9260506B2 (en) * 2011-04-07 2016-02-16 Oregon Health & Science University Treatment of retinal disorders with recombinant T cell receptor ligand (RTL)
EP2511659A1 (de) 2011-04-14 2012-10-17 Hexagon Technology Center GmbH Geodätisches Markierungssystem zur Markierung von Zielpunkten
KR102112002B1 (ko) 2011-04-29 2020-05-18 셀렉타 바이오사이언시즈, 인크. 치료적 단백질에 대해 면역 반응을 감소시키는 관용원성 합성 나노운반체
MX2014001142A (es) 2011-07-29 2014-02-27 Selecta Biosciences Inc Nanoportadores sinteticos que generan respuestas inmunitarias humorales y de linfocitos t citotoxicos (ctl).
US9043996B2 (en) 2011-10-28 2015-06-02 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
CA2852962C (en) 2011-10-28 2022-05-03 Regeneron Pharmaceuticals, Inc. Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules
US9591835B2 (en) 2011-10-28 2017-03-14 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
RS56656B1 (sr) 2011-10-28 2018-03-30 Regeneron Pharma Miševi sa genetski modifikovanim glavnim kompleksom gena tkivne podudarnosti
AU2013207489A1 (en) * 2012-01-06 2014-08-28 Oregon Health & Science University Partial MHC constructs and methods of use
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
KR102579405B1 (ko) 2013-02-20 2023-09-18 리제너론 파아마슈티컬스, 인크. 사람화된 ｔ-세포 보조-수용체를 발현하는 마우스
KR102211267B1 (ko) 2013-02-22 2021-02-04 리제너론 파아마슈티컬스, 인크. 사람화된 주요 조직적합성 복합체를 발현하는 마우스
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
JP2017500285A (ja) 2013-11-04 2017-01-05 ユーティーアイ リミテッド パートナーシップ 持続的免疫療法のための方法および組成物
CA2955984A1 (en) 2014-07-22 2016-01-28 The University Of Notre Dame Du Lac Molecular constructs and uses thereof
MX2017012829A (es) 2015-04-06 2018-02-23 Regeneron Pharma Respuestas inmunitarias mediadas por células t humanizadas en animales no humanos.
US12011480B2 (en) 2015-05-06 2024-06-18 Uti Limited Partnership Nanoparticle compositions for sustained therapy
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
US20170196957A1 (en) * 2016-01-08 2017-07-13 Oregon Health & Science University Recombinant t cell receptor ligand compositions and methods for treatment of prostate cancer
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation
MA49288A (fr) 2017-04-27 2020-03-04 Juno Therapeutics Gmbh Reactifs particulaires oligomères et leurs méthodes d'utilisation
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
EP4228693A1 (de) 2020-10-13 2023-08-23 Janssen Biotech, Inc. Biotechnologisch hergestellte t-zell-vermittelte immunität, materialien und andere verfahren zur modulation eines clusters der differenzierung iv und/oder viii

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194425A (en) * 1988-06-23 1993-03-16 Anergen, Inc. Mhc-mediated toxic conjugates useful in ameliorating autoimmunity
US6106840A (en) 1988-06-23 2000-08-22 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
US5130297A (en) 1988-06-23 1992-07-14 Anergen, Inc. Conjugates useful in ameliorating autoimmunity MHC-II-peptide
US5260422A (en) 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
US5468481A (en) 1988-06-23 1995-11-21 Amergen, Inc. MHC class II-peptide conjugates useful in ameliorating autoimmunity
US5976551A (en) * 1991-11-15 1999-11-02 Institut Pasteur And Institut Nationale De La Sante Et De La Recherche Medicale Altered major histocompatibility complex (MHC) determinant and method of using the determinant
US5734023A (en) 1991-11-19 1998-03-31 Anergen Inc. MHC class II β chain/peptide complexes useful in ameliorating deleterious immune responses
US5583031A (en) 1992-02-06 1996-12-10 President And Fellows Of Harvard College Empty major histocompatibility class II heterodimers
US5820866A (en) 1994-03-04 1998-10-13 National Jewish Center For Immunology And Respiratory Medicine Product and process for T cell regulation
AU696177B2 (en) * 1994-07-29 1998-09-03 Sunol Molecular Corporation Mhc complexes and uses thereof
US7074904B2 (en) 1994-07-29 2006-07-11 Altor Bioscience Corporation MHC complexes and uses thereof
US5595881A (en) 1994-08-09 1997-01-21 Anergen, Inc. Method for the detection of antigen presenting cells
US5635363A (en) * 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
US5869270A (en) 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
WO1999014236A1 (en) 1997-09-16 1999-03-25 Oregon Health Sciences University Recombinant mhc molecules useful for manipulation of antigen-specific t-cells
US6232445B1 (en) 1997-10-29 2001-05-15 Sunol Molecular Corporation Soluble MHC complexes and methods of use thereof

Also Published As

Publication number Publication date
CY1110274T1 (el) 2015-01-14
US20020176864A1 (en) 2002-11-28
EP1017721A4 (de) 2003-04-09
PT1017721E (pt) 2009-05-07
JP4485679B2 (ja) 2010-06-23
EP1017721B1 (de) 2009-02-25
AU9375098A (en) 1999-04-05
AU741130B2 (en) 2001-11-22
JP2001516571A (ja) 2001-10-02
DE69840600D1 (de) 2009-04-09
US20080064859A1 (en) 2008-03-13
US6815171B2 (en) 2004-11-09
EP1017721A1 (de) 2000-07-12
ES2323098T3 (es) 2009-07-06
CA2302779A1 (en) 1999-03-25
CA2302779C (en) 2010-02-02
US7265218B2 (en) 2007-09-04
US20050074853A1 (en) 2005-04-07
US6270772B1 (en) 2001-08-07
WO1999014236A1 (en) 1999-03-25
DK1017721T3 (da) 2009-04-20

Similar Documents

Publication Publication Date Title
ATE423789T1 (de) Rekombinante mhc-moleküle welche nützlich sind für die manipulation von antigen-spezifischen t- zellen
WO2006102170A3 (en) Recombinant mhc molecules useful for manipulation of antigen-specific t cells
DE69638269D1 (de) Hochaffine humane antikörper gegen tumorantigene
ATE269402T1 (de) Ikk-beta proteine, nukleinsäuren und verfahren
ATE316982T1 (de) Mehrere zytokin-antikörper komplexen
NO20100685L (no) Polypeptid samt anvendelse derav og peptidkompleks, og fremgangsmate for identifisering av et organisk eller uorganisk molekyl
ATE361364T1 (de) Antikörper gegen die ed-b domäne von fibronektin, ihre herstellung und verwendungen
ATE394484T1 (de) Smad 6 und dessen anwendungen
DE60030769D1 (de) Verfahren zur behandlung von entzündungen
PT1157042E (pt) Produção de anticorpos tetravalentes
DE69635406D1 (de) Chemokinrezeptor 88c sowie dessen antikörper
ATE268385T1 (de) Mykrobakterielle proteine, mikroorganismen welche diese produzieren und ihre verwendung als impfstoff und zum nachweis von zuberkulose
ATE365744T1 (de) Nukleinsäuremoleküle, proteine und peptide, die im zusammenhang stehen mit dickdarmzellen und dickdarm-krebszellen
ATE404587T1 (de) Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
DK0640135T3 (da) Immunoglobulinbindende proteiner, der er afledt af protein L, og anvendelser af disse
ATE270303T1 (de) Gc1q-rezeptor, daran bindende hiv-1 gp120-region, verwandte peptide und antikörper
DE69434384D1 (de) Metalkomplexbildner
ES2232860T3 (es) Proteinas recombinantes de ribonucleasa.
DE69504959T2 (de) Humanisierte monoklonale antikörper gegen humanes interleukin - 4
ATE222654T1 (de) Verfahren und mittel zum nachweis von antikörpern gegen treponema pallidum
DE59508137D1 (de) Spezifische bindungssubstanzen für antikörper und deren verwendung für immunoassays oder vakzine
FI970735A0 (fi) Menetelmät autoimmuunisairauksien käsittelyyn käyttökelpoisten yhdisteiden identifioimiseksi
ES2191033T3 (es) Alergenos recombinantes de cladosporium herbarum.
PL340728A1 (en) Histamine and serotonin bonding molecules
DE69631624D1 (de) Antikörper gegen menschliches restrictin

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1017721

Country of ref document: EP